Back to index

Cancer Chemotherapy Regimen for Stomach Cancer

 FDC                                                   gastric(62)
  fluorouracil.... 300 mg/sqm IV days 1 to 5.
  adriamycin...... 40 mg/sqm IV day 1.
  cisplatin....... 60 mg/sqm IV day 1 with hydration.
  FREQUENCY....... Repeat cycle every 5 weeks.

    Moertel CG.  Rubin J.  O'Connell MJ.  Schutt AJ.  Wieand HS. A 
    phase II study of combined 5-fluorouracil, doxorubicin, and 
    cisplatin in the treatment of advanced upper gastrointestinal 
    adenocarcinomas. Journal of Clinical Oncology.  4(7):1053-7, 
    1986 Jul. 
    In a phase II study of 67 patients with upper gastrointestinal 
    carcinomas and measurable disease without previous 
    chemotherapy, we have evaluated the combination of intensive 
    course 5-fluorouracil (5-FU) (300 mg/m2/d for five days) 
    doxorubicin (40 mg/m2 on day 1), and cisplatin (60 mg/m2 on 
    day 1). Courses were repeated every 5 weeks. Among 26 patients 
    with gastric carcinoma, a 50% regression rate was obtained 
    with a median survival for all patients of 9 months. Among 29 
    patients with pancreatic carcinoma, the regression rate was 
    21% and the median survival was 4 months. Regressions were 
    also observed in smaller numbers of patients with carcinomas 
    of the gallbladder and ampulla of Vater, as well as in 
    cholangiocellular carcinoma of the liver. Toxic reactions were 
    usually clinically tolerable and consisted primarily of 
    nausea, vomiting, stomatitis, diarrhea, leukopenia, and 
    alopecia. Phase III studies are in progress to place the value 
    of this experimental regimen into clinical perspective. 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us